Please login to the form below

Not currently logged in

market access

This page shows the latest market access news and features for those working in and with pharma, biotech and healthcare.

NHS England wants money-back guarantee on Orkambi

NHS England wants money-back guarantee on Orkambi

It has proposed a two-year managed access arrangement for Orkambi and Symekvi. ... NHS England has pointed out that just in the last few weeks it has signed novel market access deals with Roche and Biogen, and called on Vertex to be similarly “willing

Latest news

More from news
Approximately 130 fully matching, plus 391 partially matching documents found.

Latest Intelligence

  • Breaking Bad Breaking Bad

    In brand teams, fundamental terms like market segment or positioning are frequently used with no regard for their tight, technical meaning. ... Conflict vs cooperation. The very essence of organisational effectiveness is the coordination of separate,

  • The first, my last, my everything The first, my last, my everything

    The stampede towards it is an inevitable progression from patient empowerment, with digital advancement providing increased opportunities for people to access information about health. ... Obviously, you’ll need to talk to other stakeholders too –

  • The Orkambi row explained The Orkambi row explained

    Is the UK an extreme outlier in terms of market access for Orkambi? ... April 2018: Vertex meets with NHSE to discuss access to Orkambi and future treatments.

  • #OrkambiNow? #OrkambiNow?

    This would represent a transition towards an outcomes-based reimbursement system, which is certain to be central to market access for many novel drugs in the future. ... For people with CF and these rare conditions, this vision of a less adversarial and

  • “Brexit has been a catalyst for UK clinical research... it’s turbocharged change” “Brexit has been a catalyst for UK clinical research... it’s turbocharged change”

    NHS England is now the dominant market access gatekeeper in the all-important specialised medicines field. ... can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah and Gilead’s Yescarta providing an encouraging

More from intelligence
Approximately 59 fully matching, plus 127 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 88 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 29 fully matching, plus 352 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Playing Mind Games
To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists
P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....